Since our official opening in 2023, we have established ourselves as a leading institution in cancer treatment, partnering with renowned facilities like Peking University Cancer Hospital. Our focus is on delivering innovative therapies and comprehensive care to improve outcomes for our patients.

Collaborative Efforts in Oncology

The pursuit of a cure for leukemia in adults requires collaboration across various medical disciplines. Our partnership with Peking University Cancer Hospital has enabled us to enhance our capabilities significantly. Together, we are advancing key department construction, talent training, and scientific research, particularly in the field of digestive tumors and related cancers. This alliance strengthens our ability to provide cutting-edge treatments and fosters an environment of continuous learning and improvement.

Advancements in Nuclear Medicine

At GoBroad, we are proud to be at the forefront of advancements in nuclear medicine, which plays a crucial role in our efforts to find a cure for leukemia in adults. In November 2023, we obtained the clinical application qualification for lutetium-177, a breakthrough in targeted therapy for various cancers. Our four dedicated radionuclide therapy wards allow us to treat up to 200 patients annually, providing them with access to innovative therapies that can significantly improve their prognosis.

Our commitment to radiation safety is paramount. We have implemented strict radiation shielding measures and conducted thorough safety analyses to ensure that our facilities meet the highest standards of protection for both patients and staff. This focus on safety allows us to provide effective treatments while minimizing potential risks, thereby enhancing the overall patient experience.

A Multidisciplinary Approach

Our unique "double PI" model, which involves both nuclear medicine and clinical experts, exemplifies our commitment to a multidisciplinary approach in the quest for a cure for leukemia in adults. This collaboration not only reduces the burden on individual researchers but also maximizes the strengths of each specialty. By working together, we can conduct comprehensive studies and clinical trials that yield valuable insights and pave the way for new treatment options.

Conclusion

GoBroad is committed to advancing the hunt for a treatment for adult leukemia by means of creative partnerships and ground-breaking research. Our collaboration with Peking University Cancer Hospital improves patient care and clinical resources, and our developments in nuclear medicine open up new therapeutic options. We are still dedicated to enhancing the quality of life for adults with leukemia as we investigate and apply innovative treatments. Together, we are working toward a time when our patients will have hope and healing due to the availability of viable therapies.